טוען...
Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease
β-Blockers reduce mortality and improve symptoms in people with heart disease; however, current clinically available β-blockers have poor selectivity for the cardiac β(1)-adrenoceptor (AR) over the lung β(2)-AR. Unwanted β(2)-blockade risks causing life-threatening bronchospasm and reduced efficacy...
שמור ב:
| הוצא לאור ב: | FASEB J |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Federation of American Societies for Experimental Biology
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5471521/ https://ncbi.nlm.nih.gov/pubmed/28400472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201601305R |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|